GlassScriptPhysician profile
Richard E Mohr
NPI 1396939393
$6,741.28
in general payments reported to CMS, 2019-2025
45 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $630 · 2021: $620 · 2022: $1,022 · 2023: $1,432 · 2024: $959 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.79 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,924.41 | 2019-2025 | |
| Novo Nordisk INC | $665.87 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $376.19 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Lilly USA, LLC | $275.44 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $258.21 | 2019-2020 | |
| Amgen INC. | $239.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $222.15 | 2019-2025 | |
| Astellas Pharma US INC | $168.67 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $147.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $138.47 | 2019-2022 | |
| Abbott Laboratories | $124.29 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.13 | 2019-2025 | Xifaxan |
| Horizon Therapeutics Plc | $89.81 | 2019-2022 | |
| Forte Bio-Pharma LLC | $89.12 | 2020-2025 | Prolate, Tanlor, Nalocet |
| Glaxosmithkline, LLC. | $69.45 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.